Skip to main content
Premium Trial:

Request an Annual Quote

Dale Pfost, Donald Marvin, Klaus Schollmeier, Tristan Orpin

Premium

Dale Pfost has resigned as president and CEO of Orchid BioSciences of Princeton, N.J., and Donald Marvin has resigned as senior vice president and general manager, the company announced this week. Orchid has established a search committee to find a replacement for Pfost who is leaving to pursue other opportunities. Pfost was chairman of the company from November 1996 to September 2002.

Klaus Schollmeier has been appointed chief executive officer of Graffinity Pharmaceuticals of Heidelberg, Germany, effective Jan. 1, 2003. Schollmeier most recently served as managing director of the healthcare/biotechnology group at ING-BHF Bank and previously held senior management positions at BASF Pharma. Schollmeier holds a PhD in biology from the University of D sseldorf and has been an adjunct research associate professor at Boston University Medical School.

Tristan Orpin was named vice president of worldwide sales for San Diego-based Illumina, the company announced last week. Orpin, formerly vice president for sales and marketing for Sequenom, will head sales of BeadArray and Oligator technology for Illumina. Previously, Orpin worked in sales for Bio-Rad Laboratories where he was Australasian general manager for the company’s life sciences division. Orpin has a BS degree in biochemistry from the University of Melbourne, Australia.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more